Ipsen and Biomunex Announce Exclusive Worldwide License Agreement for MAIT Cell Activator
December 05, 2024
December 05, 2024
BOSTON, Massachusetts, Dec. 5 -- Goodwin, a law firm, issued the following news release:
Goodwin Paris advised Biomunex Pharmaceuticals, a biopharmaceutical company with operations in Paris (France) and Cambridge (MA, USA), on its exclusive global licensing agreement with Ipsen for the BMX-502 program. BMX-502, a MAIT cell activator (also known as a "MAIT engager"), represents a new therapeutic class in immuno-oncology.
Ipsen, a global biopharmaceutical leader . . .
Goodwin Paris advised Biomunex Pharmaceuticals, a biopharmaceutical company with operations in Paris (France) and Cambridge (MA, USA), on its exclusive global licensing agreement with Ipsen for the BMX-502 program. BMX-502, a MAIT cell activator (also known as a "MAIT engager"), represents a new therapeutic class in immuno-oncology.
Ipsen, a global biopharmaceutical leader . . .